Merck KGaA/MRK

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1YMAX

About Merck KGaA

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Ticker

MRK

Sector

Healthcare

Trading on

XETRA

Industry

Pharmaceuticals

CEO

-

Employees

62,345

Headquarters

Darmstadt, Germany

Merck KGaA Metrics

BasicAdvanced
€75B
Market cap
27.52
P/E ratio
€6.26
EPS
0.69
Beta
€2.20
Dividend rate
1.28%
Dividend yield
€75B
0.69029
€2.20
1.29
0.789
27.866
35.456
40.93%
13.35%
4.57%
10.07%
27.52
3.6
2.67
22.41
38.17
1.28%
-6.75%
-16.08%
5.37%
6.11%
16.26%

What the Analysts think about Merck KGaA

Analyst Ratings

Majority rating from 20 analysts.
Buy

Merck KGaA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
13.55% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€5.1B
-2.01%
Net income
€694M
18.43%
Profit margin
13.55%
20.87%

Merck KGaA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.16%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
€2.20
€2.07
€1.85
€2.06
-
Expected
€2.19
€1.99
€1.91
€1.87
€2.02
Surprise
0.43%
3.91%
-3.28%
10.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and Deutsche Börse. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Merck KGaA stock?

Merck KGaA (MRK) has a market cap of €75B as of June 14, 2024.

What is the P/E ratio for Merck KGaA stock?

The price to earnings (P/E) ratio for Merck KGaA (MRK) stock is 27.52 as of June 14, 2024.

Does Merck KGaA stock pay dividends?

Yes, the Merck KGaA (MRK) stock pays dividends to shareholders. As of June 14, 2024, the dividend rate is €2.2 and the yield is 1.28%. Merck KGaA has a payout ratio of 40.93% on a trailing twelve-month basis.

When is the next Merck KGaA dividend payment date?

The next Merck KGaA (MRK) dividend payment date is unconfirmed.

What is the beta indicator for Merck KGaA?

Merck KGaA (MRK) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Merck KGaA stock price target?

The target price for Merck KGaA (MRK) stock is €186.06, which is NaN% below the current price of €. This is an average based on projections from 17 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Merck KGaA stock

Buy or sell Merck KGaA stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing